- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints - - Obexelimab was well tolerated and no new safety signals were observed - - Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application

Jan. 05, 2026 -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products. The study, conducted using a validated in

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SynuSight Biotech (“SynuSight”), a biotechnology company dedicated to the development of diagnostic solutions for neurodegenerative diseases and ABLi Therapeutics (“ABLi”), a biotechnology company developing disease-modifying therapeutics in Parkinson’s disease, have entered into non-exclusive clinical use license agreement tha

Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic carcinoma (ACC) Jan. 06, 2026 -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the successful close of its acquisition of Mersana Therapeutics, Inc., (NASDAQ: MRSN) (

Jan. 05, 2026 -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the final patient has been dosed in Cohort B (high-dose cohort, 4.50×10¹³ viral genomes (vg) per patient) of the ongoing MUSIC-HFpEF Phase 1/2a clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF). The patient was successfully treated using Medera's pr

-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- Jan. 05, 2026 -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the high selectivity, pi

Jan. 05, 2026 -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa’s proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. “This is an important mil

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operation

- Company expects topline data from the study in 2027 Jan. 05, 2026 -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the completion of enrollment in the Phase 2 ARTEMIS trial evaluating AGA2118, a bispecific antibody targeting sclerostin and Dickkopf-1 (DKK1), for the treatment of osteoporosis. “We are pleased to announce the successful completion of

TARA-002 selected for FDA manufacturing development and readiness pilot program Jan. 05, 2026 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations for TARA-002, the Company’s investigational cell-based therapy, for the treatment of pediatric patients with macrocysti